CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD

被引：3
|
作者：
Edwards, David K.
Javidi-Sharifi, Nathalie
Rofelty, Angela
Gordon, Max
Roth-Carter, Riley
Tardi, Paul
Mayer, Lawrence
Tyner, Jeffrey W.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1087
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Use of FLT3 Inhibitors in AML
    Smith, Catherine C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S92 - S94
  • [42] Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
    Yang, Xiaochuan
    Sexauer, Amy
    Levis, Mark
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (01) : 61 - 72
  • [43] Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
    Takahashi, Koichi
    Kantarjian, Hagop
    Pemmaraju, Naveen
    Andreeff, Michael
    Borthakur, Gautam
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Pierce, Sherry
    Luthra, Rajyalakshmi
    Cardenas-Turanzas, Marylou
    Estrov, Zeev
    Ravandi, Farhad
    Cortes, Jorge
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) : 659 - 666
  • [44] CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
    Jetani, Hardikkumar
    Garcia-Cadenas, Irene
    Nerreter, Thomas
    Thomas, Simone
    Rydzek, Julian
    Briones Meijide, Javier
    Bonig, Halvard
    Herr, Wolfgang
    Sierra, Jordi
    Einsele, Hermann
    Hudecek, Michael
    LEUKEMIA, 2018, 32 (05) : 1168 - 1179
  • [45] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [46] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [47] Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
    Green, Alexa S.
    Maciel, Thiago T.
    Hospital, Marie-Anne
    Yin, Chae
    Mazed, Fetta
    Townsend, Elizabeth C.
    Pilorge, Sylvain
    Lambert, Mireille
    Paubelle, Etienne
    Jacquel, Arnaud
    Zylbersztejn, Florence
    Decroocq, Justine
    Poulain, Laury
    Sujobert, Pierre
    Jacque, Nathalie
    Adam, Kevin
    So, Jason C. C.
    Kosmider, Olivier
    Auberger, Patrick
    Hermine, Olivier
    Weinstock, David M.
    Lacombe, Catherine
    Mayeux, Patrick
    Vanasse, Gary J.
    Leung, Anskar Y.
    Moura, Ivan C.
    Bouscary, Didier
    Tamburini, Jerome
    SCIENCE ADVANCES, 2015, 1 (08):
  • [48] FLT3 INHIBITORS DRIVE CLONAL TRILINEAGE TERMINAL DIFFERENTIATION OF NPM1-MUTATED/FLT3-ITD AML MIMICKING HEMATOLOGICAL RESPONSE
    Martelli, M. P.
    Ciurnelli, R.
    Cardinali, V.
    Pierangeli, S.
    Cecchini, D.
    Bigerna, B.
    Gionfriddo, I.
    Papayannidis, C.
    Martinelli, G.
    Ascani, S.
    Falzetti, F.
    Falini, B.
    HAEMATOLOGICA, 2018, 103 : S19 - S19
  • [49] PRE-CLINICAL EVALUATION OF NOVEL FLT3 INHIBITORS EFFECTIVE IN FLT3-ITD ACUTE MYELOID LEUKEMIA
    Minson, Katherine
    Sherick, Alisa Lee
    DeRyckere, Deborah
    Wang, Xiaodong
    Frye, Stephen
    Earp, H. Shelton, III
    Graham, Doug
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S52 - S52
  • [50] HYPOXIA REGULATES FLT3-ITD EXPRESSION AND FUNCTION IN AML CELL-LINES HARBOURING A FLT3-ITD MUTATION
    Sironi, S.
    Wagner, M.
    Vasold, J.
    Drolle, H.
    Fiegl, M.
    ANNALS OF HEMATOLOGY, 2013, 92 : S12 - S13
12345